Avastin Breast Cancer Approval Memo Comes Back To Haunt FDA’s Pazdur
Executive Summary
Reflected in the regulatory struggle over Avastin’s (bevacizumab) metastatic breast cancer claim is the uncertainty underlying drug approval decisions for FDA and sponsors, laying bare the sometimes tenuous evidence with which the agency has to work.
You may also be interested in...
“Not Another Avastin,” FDA Panel Warns Genentech At Perjeta Review
Under questioning from FDA’s Richard Pazdur, VP Sandra Horning says company would be willing to withdraw pertuzumab’s neoadjuvant indication if results from ongoing adjuvant study are “clearly negative”; advisory committee members say they expect sponsor to bow out more gracefully than it did in the fight over bevacizumab’s breast cancer claim.
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.
Oncology Drug Applications Migrate As Part Of FDA's Reorganization Of OODP
Many NDAs, BLAs and INDs for cancer drugs are being reassigned to new review divisions as part of a reorganization of FDA’s Office of Oncology Drug Products.